All In Biotech

Free tool

FAERS Monitor: Nulytely

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 019797 or its brand name (Nulytely, Polyethylene Glycol 3350, Potassium Chloride, Sodium Bicarbonate, Sodium Chloride). Reports on generic versions are filed under their own applications.

Reports

248

Serious

151

61% of reports

Hospitalization

79

Death reported

30

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • vomiting34
  • nausea28
  • drug ineffective14
  • fatigue14
  • pneumonia14
  • chronic kidney disease13
  • abdominal distension12
  • renal failure12
  • asthenia11
  • constipation11
  • diarrhoea11
  • dyspnoea11
  • headache11
  • acute kidney injury10
  • death10

Reports by year received

View as table
YearReports
20052
20061
20071
20081
20093
20102
20117
20122
201317
20145
201516
201619
201724
201829
201923
202024
20217
202225
20239
202415
202516

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,911 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
chronic kidney diseaseSignal1314.58.5151
abdominal distensionSignal129.85.686
renal failureSignal127.74.463
vomitingSignal346.14.5144
acute kidney injurySignal105.53.033
constipationSignal114.32.425
pneumoniaSignal143.72.225
nauseaSignal283.02.137
astheniaSignal112.51.48
dyspnoea111.60.92
fatigue141.50.92
headache111.50.81
diarrhoea111.40.81
death101.00.50
drug ineffective140.90.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.